Lee H et al. (2022), Uncoupling the BMP receptor antagonist function...

XB-ART-58804

J Biol Chem 2022 Feb 01;2982:101586. doi: 10.1016/j.jbc.2022.101586.

Show Gene links Show Anatomy links

Uncoupling the BMP receptor antagonist function from the WNT agonist function of R-spondin 2 using the inhibitory peptide dendrimer RWd.

Lee H , Sun R , Niehrs C .

Abstract
Signaling by bone morphogenetic proteins (BMPs) plays pivotal roles in embryogenesis, adult tissue homeostasis, and disease. Recent studies revealed that the well-established WNT agonist R-spondin 2 (RSPO2) is also a BMP receptor (BMP receptor type 1A) antagonist, with roles in early Xenopus embryogenesis and human acute myeloid leukemia (AML). To uncouple the BMP antagonist function from the WNT agonist function and to promote development of AML therapeutics, here we identified a 10-mer peptide (RW) derived from the thrombospondin 1 domain of RSPO2, which specifically prevents binding between RSPO2 and BMP receptor type 1A without altering WNT signaling. We also show that a corresponding RW dendrimer (RWd) exhibiting improved half-life relieves inhibition of BMP receptor signaling by RSPO2 in human AML cells, reduces cell growth, and induces differentiation. Moreover, microinjection of RWd in Xenopus embryos ventralizes the dorsoventral embryonic patterning by upregulating BMP signaling without affecting WNT signaling. Our study corroborates the function of RSPO2 as a BMP receptor antagonist and provides a proof of concept for pharmacologically uncoupling BMP antagonist from WNT agonist functions of RSPO2 using the inhibitor peptide RWd with enhanced target selectivity and limited side effects.

PubMed ID: 35032551
Article link: J Biol Chem

Species referenced: Xenopus tropicalis
Genes referenced: acvr1 acvr2a acvr2b bmp4 bmpr1a bmpr2 crisp1.3 furin lgr4 lrp6 mapk14 rnf43 rspo2 rspo3 runx1 sdc2 smad1 szl thbs1 wnt3a znrf3
GO keywords: Wnt signaling pathway [+]
Antibodies: Ctnnb1 Ab1 MapK1 Ab5 Mapk1 Ab1 Smad1 Ab13 Smad1 Ab8 Tuba4a Ab3

Disease Ontology terms: acute myeloid leukemia

Article Images: [+] show captions

	Figure 1Design and validation of peptide to block RSPO2–BMPR1A interaction. A, scheme for design of RSPO2TSP1-derived peptide to block RSPO2 access to BMPR1AECD for interaction. B, amino acid sequence of human RSPO2TSP1 domain (amino acids 142–206; black boxes) and overlapping peptide candidates derived from the TSP1 domain. About 11 peptides consisting of 10 to 14 amino acids were designed with 5 mer offset. Designated names of corresponding peptides are indicated on the left side. Note that cysteine residues in the middle of each peptide were exchanged into serine residues for synthesis. C, scheme for in vitro competitive binding assay of (D). HA-fused RSPO2TSP1 were treated on anti-HA antibody-coated plate as baits, followed by AP-fused BMPR1AECD treatment for 3 h with or without 100 μM of peptide candidates. Binding between RSPO2TSP1 and BMPR1AECD was detected with AP activity. D, in vitro binding assay for RSPO2TSP1 and BMPR1AECD interaction competing with overlapping peptides. Note that RW peptide exhibited the strongest inhibition for RSPO2TSP1–BMPR1A binding. n = 2 to 3 experimental replicates. Data are displayed as means ± SD. ns; ∗∗∗p < 0.001 from two-tailed unpaired t test. E, IC50 curve for RW peptide to inhibit RSPO2TSP1–BMPR1AECD interaction. Note that IC50 of RW for RSPO2TSP1–BMPR1AECD is 42 μM. F, amino acid sequence alignment of human RSPO1–4 with RW peptide. Conserved amino acids are indicated with green boxes. G, scheme for in vitro binding assay to analyze direct binding between RW peptide and BMPR1AECD in (G). Biotinylated RW or TK peptide was treated on streptavidin-coated plate as a bait, followed by BMPR1AECD–AP treatment. Binding of peptide-BMPR1AECD was detected with AP activity. H, in vitro binding assay showing direct RW and BMPR1AECD interaction. n = 3 experimental replicates. Data are displayed as means ± SD. ns; ∗∗p < 0.01 from two-tailed unpaired t test. AP, alkaline phosphatase; BMPR1A, BMP receptor type 1A; BMPR1AECD, extracellular domain of BMPR1A; FU, furin domain; HSPG, heparin sulfate proteoglycan; ns, not significant; RSPO2, R-spondin 2; RSPO2TSP1, TSP1 domain of RSPO2; SDC, syndecan; TSP1, thrombospondin 1 domain.
	Figure 2RW dendrimer blocks RSPO2–BMPR1A interaction at the cell membrane. A, cartoons illustrating three different RW dendrimers used in the study. B, scheme for cell surface–binding assay in (C–H). Cells were transfected with BMPR1A or LGR4 DNA and treated with RSPO2/3-AP with or without 20 μM dendrimers for 3 h as indicated. Binding was detected as purple stain on cell surface by chromogenic AP assay. C, images of cells transfected with DNA and treated with RSPO2-AP and 20 μM non-PEGylated dendrimers as indicated. Data show a representative from three independent experiments. The scale bar represents 1 mm. D, quantification of (C). n = 3 biologically independent samples. Data are displayed as means ± SD. E, images of cells transfected with DNA and treated with RSPO2-AP and 20 μM N-PEGylated dendrimers as indicated. Data show a representative from three independent experiments. The scale bar represents 1 mm. F, quantification of (E). n = 3 biologically independent samples. Data are displayed as means ± SD. G, images of cells transfected with DNA and treated with RSPO3-AP and 20 μM non-PEGylated dendrimers as indicated. Data show a representative from three independent experiments. The scale bar represents 0.5 mm. H, quantification of (G). n = 3 biologically independent samples. Data are displayed as means ± SD. AP, alkaline phosphatase; BMPR1A, BMP receptor type 1A; LGR4, leucine-rich repeat containing G protein–coupled receptor 4; PEG, PEGylation; RSPO2, R-spondin 2.
	Figure 3RW dendrimer augments BMP4–BMPR1A signaling. A, Western blot analysis of phosphorylated Smad1 (pSmad1) and total Smad1 (tSmad1) in HEPG2 cells stimulated by BMP4, treated with or without RSPO2 and 0.5 μM dendrimers for 1 h as indicated. Cells were starved 3 h before the stimulation. B, Western blot analysis of pSmad1 and tSmad1 in HEPG2 cells stimulated by BMP4, treated with or without RSPO3 and 0.5 μM dendrimers for 1 h as indicated. Cells were starved 3 h before the stimulation. C, Western blot analysis of pSmad1 and tSmad1 in HEPG2 cells treated with or without 0.5 μM dendrimers for 3 days as indicated. BMP4 was treated as a control. Cells were starved 6 h before the stimulation. D, Western blot analysis of pSmad1 and tSmad1 in H1581 cells treated with or without 0.5 μM dendrimers for 3 days as indicated. E, Western blot analysis of phosphorylated P38 (pP38), phosphorylated P44/42 (pP44/42), total P38 (tP38), and total P44/42 (tP44/42) MAP kinases in HEPG2 cells stimulated by BMP4, treated with or without RSPO2 and 0.5 μM dendrimers for 1 h as indicated. Cells were starved overnight before the stimulation. F, Western blot analysis of activated β-catenin in H1581 cells treated with WNT3A and 0.5 μM dendrimers as indicated. Tubulin was used as a control. G, immunofluorescence in H1581 cells transfected with BMPR1A-HA upon 0.5 μM RW and KR dendrimer treatment or siRSPO2 treatment for 3 days. BMPR1A (red) was stained against HA antibody. The scale bar represents 20 μm. H, quantification of cells harboring membrane-localized BMPR1A from (G). BMP4, bone morphogenetic protein 4; BMPR1A, BMP receptor type 1A; HA, hemagglutinin; HEPG2, human hepatocellular carcinoma cell line; MAP, mitogen-activated protein; RSPO2, R-spondin 2; Smad, small mothers against decapentaplegic.
	Figure 4RW dendrimers induce THP-1 differentiation and growth inhibition. A–C, Western blot analysis of phosphorylated Smad1 (pSmad1) and total Smad1 (tSmad1) in THP-1 cells stimulated by dendrimers for 3 days as indicated. A, cells were treated with 0.5 μM nonmodified dendrimer. B, cells were treated with 0.5 μM N-PEG dendrimer. C, cells were treated with 2.0 μM C-PEG dendrimer. D–F, quantification of CD11B+ THP-1 cells in the flow cytometry analysis. D, cells were treated with 0.5/1.0/1.5 μM nonmodified dendrimer for 3 days (E), cells were treated with 2.0/3.0 μM N-PEG dendrimer for 3 days (F), and cells were treated with 3.0/4.0 μM C-PEG dendrimer for 3 days. CD11B− cells were defined by the staining of isotype-matched control antibody. G, quantification of CD11B+ THP-1 cells in the flow cytometry analysis. Cells were treated with 2.0 μM N-PEG dendrimer for 3 days. After costimulation with 0.5/1.0 μM LDN-193189 for 24 h, cells were harvested for a flow cytometry analysis. H–J, cell viability assay of THP-1 and iHAF cells upon dendrimer treatment. THP-1 and iHAF cells were incubated with increasing amounts of dendrimers for 48 h. Cell viability was measured with a luminescent-based assay. iHAF, immortalized human adult fibroblast cell line; RLU, relative light unit; Smad, small mothers against decapentaplegic.
	Figure 5RW dendrimer increases BMP signaling during Xenopus embryogenesis independently of WNT signaling. A, amino acid sequence comparison of RSPO2 TSP1 domain in human, mouse, and Xenopus. Note that RW peptide sequence derived from human RSPO2 is highly conserved among species (green boxes). B, microinjection strategy for (C–H). Emulsion of RWd or KRd was injected into the blastocoel of stage 9 Xenopus tropicalis embryos and cultured until tailbud (stage 28) (C and D) or harvested at gastrulae and neurulae (stage 11; E and F; stage 18, G and H). bmp4 mRNA was injected radially at four-cell stage embryos as a control. C, representative phenotypes of Xenopus tropicalis tailbud (stage 28) injected as indicated. Dashed lines, head size. Arrowheads, enlarged ventral structure. Note that RWd-injected tailbud phenocopies bmp4 overexpressed tailbud. The scale bar represents 1 mm. D, quantification of embryonic phenotypes shown in (C). “Ventralized” represents embryos with both small head and enlarged ventral structure, reminiscent of BMP hyperactivation. “Short axis” refers to embryos with shorter body length, unrelated to BMP signaling. n = number of embryos. E, in situ hybridization of sizzled in Xenopus gastrulae (stage 11, dorsal to the top, vegetal view) injected as indicated. Dashed line, sizzled expressing area. The scale bar represents 0.5 mm. F, quantification of sizzled expression shown in (E). Data are pooled from two independent experiments. n = number of embryos. G and H, BMP-(vent2) reporter assay (G) and WNT-(TOPFlash) reporter assay (H) with Xenopus tropicalis neurulae (stage 18) injected with reporter plasmids at stage 3 and then injected with dendrimers at stage 9 as indicated or simultaneously injected with bmp4 mRNA or lrp6 morpholino (MO). Data are biological replicates. n = biologically independent samples and data are displayed as means ± SD, with unpaired t test. ns, not significant. ∗∗p < 0.01, ∗∗∗∗p < 0.0001 from two-tailed unpaired t test. I, model showing the mode of action for RWd to intervene RSPO2–BMPR1A and modulate BMP signaling. BMP, bone morphogenetic protein; BMPR1A, BMP receptor type 1A; D, dorsal; RSPO2, R-spondin 2; RWd, RW dendrimer; TSP1, thrombospondin 1; V, ventral.
	Figure S1. Monomeric RW peptide has low stability. (A) In vitro competitive binding assay for RSPO2TSP1 and BMPR1AECD interaction upon monomeric peptide treatment as indicated. 50 μM peptides were reconstituted and immediately treated (Day 0) or treated after 4 days of storage (Day 4). Binding was detected with AP activity. (B) Scheme for cell surface binding assay in (C-D). Cells were transfected with BMPR1A DNA, and treated with RSPO2-AP with or without PEGylated peptides for 3 hours or 16 hours as indicated. Binding was detected as purple stain on cell surface by chromogenic AP assay. (C) Images of cells transfected and treated with 50 μM peptides as indicated. Data shows a representative from three independent experiments. Scale bar, 0.5 mm. (D) Quantification of (C).
	Figure S2. Dendrimerization of RW peptide increased stability to block RSPO2-BMPR1A interaction. (A) In vitro competitive binding assay for RSPO2TSP1 and BMPR1AECD interaction with peptide treatment as indicated. Binding was detected with AP activity. (B) Cell surface binding assay in HEK293T cells. Cells were transfected with BMPR1A DNA, followed by treatment with RSPO2-AP and 20 μM non-PEGylated or PEGylated dendrimers for 15 hours as indicated. Binding was detected as purple stain on cell surface by chromogenic AP assay. Note that dendrimerized peptide is still able to block RSPO2-BMPR1A interaction with long-term treatment. Data shows a representative from three independent experiments. Scale bar, 0.5 mm. (C) Quantification of (B). Data are experimental replicates and displayed as means ± SD.
	Figure S3. RW dendrimers did not affect WNT signaling in THP-1 cells. (A-B) Western blot analysis of phosphorylated Smad1 (pSmad1) and total Smad1 (tSmad1) in Doxinducible shControl and shRSPO2 THP-1 cells treated with Dox and 0.5 μM non-modified dendrimers as indicated. (C-D) Western blot analysis of active β-catenin (act-β-cat) and loading control (Tub, α-Tubulin) in THP-1 cells stimulated by dendrimers for 3 days as indicated. (C), cells were treated with 0.5/1.0 μM non-modified dendrimer. (D), cells were treated with 1.0/2.0 μM N-PEG dendrimer.

References [+] :

Antebi, Combinatorial Signal Perception in the BMP Pathway. 2017, Pubmed